Alphatec Holdings, Inc. (NASDAQ:ATEC) Position Lifted by IFP Advisors Inc

IFP Advisors Inc raised its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 41.8% during the third quarter, HoldingsChannel reports. The fund owned 11,991 shares of the medical technology company’s stock after acquiring an additional 3,532 shares during the quarter. IFP Advisors Inc’s holdings in Alphatec were worth $146,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its position in shares of Alphatec by 17.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,397 shares of the medical technology company’s stock worth $83,000 after buying an additional 785 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its position in shares of Alphatec by 27.5% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 9,569 shares of the medical technology company’s stock worth $147,000 after buying an additional 2,062 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Alphatec in the 2nd quarter worth about $187,000. Amalgamated Bank bought a new position in shares of Alphatec in the 2nd quarter worth about $195,000. Finally, Tibra Equities Europe Ltd bought a new position in shares of Alphatec in the 2nd quarter worth about $263,000. Hedge funds and other institutional investors own 44.19% of the company’s stock.

In other Alphatec news, Director David R. Pelizzon acquired 4,366 shares of the stock in a transaction dated Thursday, November 11th. The shares were bought at an average price of $11.41 per share, with a total value of $49,816.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Jennifer N. Pritzker bought 2,000 shares of the firm’s stock in a transaction on Friday, August 27th. The stock was purchased at an average price of $13.26 per share, with a total value of $26,520.00. Following the completion of the acquisition, the insider now owns 38,200 shares of the company’s stock, valued at $506,532. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 76,791 shares of company stock worth $907,261. 34.38% of the stock is owned by corporate insiders.

A number of research analysts have recently issued reports on ATEC shares. Cowen started coverage on shares of Alphatec in a research report on Wednesday, August 4th. They issued an “outperform” rating and a $22.50 price target on the stock. Piper Sandler increased their price objective on shares of Alphatec from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, August 4th. Canaccord Genuity increased their price objective on shares of Alphatec from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 4th. Needham & Company LLC dropped their price objective on shares of Alphatec from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 5th. Finally, Zacks Investment Research cut shares of Alphatec from a “hold” rating to a “sell” rating in a report on Tuesday, October 5th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $20.06.

Alphatec stock opened at $11.26 on Thursday. The firm has a market cap of $1.12 billion, a PE ratio of -7.87 and a beta of 1.63. The company has a debt-to-equity ratio of 2.87, a quick ratio of 2.64 and a current ratio of 3.57. The firm’s 50-day moving average is $12.73. Alphatec Holdings, Inc. has a 52 week low of $9.30 and a 52 week high of $19.36.

Alphatec (NASDAQ:ATEC) last released its earnings results on Thursday, November 4th. The medical technology company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.20). The company had revenue of $62.88 million for the quarter, compared to analyst estimates of $61.43 million. Alphatec had a negative net margin of 61.41% and a negative return on equity of 92.96%. During the same period in the previous year, the business posted ($0.18) EPS. On average, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.35 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.

Featured Article: What sectors are represented in the Nikkei Index?

Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATEC).

Institutional Ownership by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.